Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adults

Fritz Raiser, Matthew Davis, Jeffrey Adelglass, Miranda R. Cai, Gordon Chau, Shane Cloney-Clark, Mark Eickhoff, Raj Kalkeri, Irene McKnight, Joyce Plested, Mingzhu Zhu, Lisa Dunkle the 2019nCoV-307 study team
doi: https://doi.org/10.1101/2023.03.16.23287030

Data Availability

Study information is available at https://clinicaltrials.gov/ct2/show/NCT05463068 and requests will be considered.

Back to top
Posted March 20, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adults
Fritz Raiser, Matthew Davis, Jeffrey Adelglass, Miranda R. Cai, Gordon Chau, Shane Cloney-Clark, Mark Eickhoff, Raj Kalkeri, Irene McKnight, Joyce Plested, Mingzhu Zhu, Lisa Dunkle
medRxiv 2023.03.16.23287030; doi: https://doi.org/10.1101/2023.03.16.23287030
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area